Briefing Calendar IPOs Opportunities Companies Compare Analytics Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Ali/Amlo 150/2.5 mg - Phase 3 | NVS Pipeline | CatalystAlert

Ali/Amlo 150/2.5 mg

Phase 3

Novartis AG (NVS)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Essential Hypertension

Clinical Trial

Last updated: 1/15/2026

Developer

NVS

Novartis AG

Biotechnology•Europe•NYSE

Related Pipeline

FamciclovirPhase 3

Genital Herpes

Crizanlizumab (SEG101)Phase 3

Sickle Cell Disease (SCD)

DabrafenibPhase 3

Melanoma

secukinumab low dosePhase 3

Moderate to Severe Chronic Plaque-type Psoriasis

PimecrolimusPhase 3

Atopic Dermatitis

View full pipeline